ASCO 2019 day 3

Exclusive live coverage from day three of the American Society of Clinical Oncology’s annual meeting in Chicago.

• To view all of our coverage from the preeminent cancer event, produced in association with Kantar Health, as well as additional content, visit the Spotlight on ASCO 2019 and the future of oncology

Key highlights for Sunday include:

• AstraZeneca/Merck & Co will provide one of the highlights of Sunday at ASCO, with data from the phase 3 POLO trial as a maintenance treatment in metastatic pancreatic cancer with germline BRCA mutation. This will flesh out a top-line positive result announced earlier this year.
• Novartis also has data from alpelisib, a PIK3CA class drug in patients with breast cancer. With this drug Novartis is hoping to succeed where its Swiss rival Roche has failed. Last year Roche ditched its PIK3CA drug taselisib after deciding trial data showed unpleasant side-effects would outweigh its very limited benefits in eligible patients with breast cancer. Novartis will also have further data from its breast cancer drug Kisqali.
• Also on Sunday, Roche will present early data from its “tumour agnostic” drug entrectinib in children with recurrent or refractory solid tumours, including central nervous system tumours.

ASCO 2019 day three